Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study
GM Anic, JH Lee, H Stockwell… - The Journal of …, 2011 - academic.oup.com
Background. Data on the natural history of human papillomavirus (HPV)–related genital
warts (GWs) in men are sparse. We described the distribution of HPV types in incident GWs …
warts (GWs) in men are sparse. We described the distribution of HPV types in incident GWs …
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …
the risk of developing subsequent disease after an excisional procedure for cervical …
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
EJ Dasbach, RP Insinga… - BJOG: An International …, 2008 - Wiley Online Library
Objective To assess the potential epidemiological and economic impact of a prophylactic
quadrivalent human papillomavirus (HPV)(6/11/16/18) vaccine for preventing cervical …
quadrivalent human papillomavirus (HPV)(6/11/16/18) vaccine for preventing cervical …
[PDF][PDF] Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services
J Oliphant, N Perkins - The New Zealand Medical Journal (Online), 2011 - nzmj.org.nz
Aim To review cases of genital warts diagnosed at Auckland Sexual Health Service (ASHS)
and to document any change following the introduction of the human papillomavirus (HPV) …
and to document any change following the introduction of the human papillomavirus (HPV) …
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human …
TA Westra, I Stirbu-Wagner, S Dorsman… - BMC Infectious …, 2013 - Springer
Background Infection with HPV 16 and 18, the major causative agents of cervical cancer,
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …
Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males
Background The National Human Papillomavirus (HPV) Vaccination Program for females
delivering the quadrivalent vaccine Gardasil has been included in the National …
delivering the quadrivalent vaccine Gardasil has been included in the National …
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised …
N Muñoz, R Manalastas, P Pitisuttithum, D Tresukosol… - The Lancet, 2009 - thelancet.com
Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …
most populations within 5–10 years of first sexual experience, all women remain at risk for …
Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination
EW Flagg, R Schwartz… - American journal of …, 2013 - ajph.aphapublications.org
Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age
group in a large US cohort with private insurance to detect potential decreases among …
group in a large US cohort with private insurance to detect potential decreases among …
Significant reduction in the incidence of genital warts in young men 5 years into the danish human papillomavirus vaccination program for girls and women
S Bollerup, B Baldur-Felskov, M Blomberg… - Sexually transmitted …, 2016 - journals.lww.com
Background Denmark introduced the quadrivalent human papillomavirus vaccine into the
vaccination program for 12-to 15-year-old girls in 2008 to 2009. In 2012, the program was …
vaccination program for 12-to 15-year-old girls in 2008 to 2009. In 2012, the program was …
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
X Castellsagué, N Muñoz, P Pitisuttithum… - British journal of …, 2011 - nature.com
Background: Previous analyses from a randomised trial in women aged 24–45 years have
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …